Roivant Sciences Ltd.
Roivant Sciences Ltd. operates as a biopharmaceutical and healthcare technology enterprise, concentrating on the research and development of innovative pharmaceutical solutions. The firm's pipeline features investigational therapies aimed at a diverse range of diseases. These include various oncologic malignancies (such as solid tumors), blood conditions like sickle cell disease, rare genetic disorders such as hypophosphatasia, and a spectrum of dermatological ailments including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, and acne. Additionally, their work extends to autoimmune disorders like myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, and sarcoidosis, alongside bacterial infections such as Staph aureus bacteremia. Founded in 2014, the company maintains its headquarters in London, United Kingdom.
Visit website
LLY Eli Lilly and Company |
$1139.65 | -1.23% |
JNJ Johnson & Johnson |
$256.11 | -1.42% |
ABBV AbbVie |
$260.91 | 0.45% |
MRK Merck & Co. |
$143.38 | -0.27% |
UNH UnitedHealth Group Incorp… |
$368.09 | 0.81% |